HC Wainwright Issues Pessimistic Forecast for SGMO Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Analysts at HC Wainwright decreased their FY2028 earnings estimates for shares of Sangamo Therapeutics in a research note issued on Thursday, April 2nd. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings per share of $0.27 for the year, down from their prior forecast of $0.28. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2029 earnings at $0.40 EPS and FY2030 earnings at $0.57 EPS.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Monday, March 30th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.12). The company had revenue of $14.23 million during the quarter, compared to analyst estimates of $40.25 million. Sangamo Therapeutics had a negative net margin of 310.81% and a negative return on equity of 1,070.18%.

A number of other equities research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Sangamo Therapeutics to a “strong sell” rating in a research report on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sangamo Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.50.

Sangamo Therapeutics Stock Performance

Shares of SGMO opened at $0.30 on Friday. Sangamo Therapeutics has a twelve month low of $0.21 and a twelve month high of $0.84. The firm has a market capitalization of $124.32 million, a P/E ratio of -0.68 and a beta of 1.49. The firm’s 50-day moving average is $0.38 and its two-hundred day moving average is $0.47.

Hedge Funds Weigh In On Sangamo Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. World Investment Advisors raised its position in Sangamo Therapeutics by 88.5% during the third quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 20,000 shares during the last quarter. Cetera Investment Advisers acquired a new stake in shares of Sangamo Therapeutics in the fourth quarter valued at approximately $31,000. XTX Topco Ltd acquired a new stake in shares of Sangamo Therapeutics in the second quarter valued at approximately $41,000. Engineers Gate Manager LP increased its stake in shares of Sangamo Therapeutics by 101.7% during the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 44,078 shares in the last quarter. Finally, State of Wyoming acquired a new position in shares of Sangamo Therapeutics during the 4th quarter worth approximately $47,000. 56.92% of the stock is currently owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.